Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fed State Clear all

Conditions: Healthy Volunteers
Interventions: TS-134, Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Adults
Interventions: Dazucorilant, Itraconazole; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted; Drug
Lead sponsor: Medicines for Malaria Venture; Other
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Pharmacokinetics
Interventions: ESK-001, Rabeprazole; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Lymphoma, Malignant, Advanced Solid Neoplasms
Interventions: TAK-659; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Detroit, Michigan • The Bronx, New York

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Prasugrel ODT1 - Tablet, Prasugrel ODT2 - Tablet, Prasugrel ODT2 - Suspension; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: PF-06412562; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cognitive Dysfunction, Schizophrenia
Interventions: KYN-5356, placebo; Drug
Lead sponsor: Kynexis B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetic Kidney Disease
Interventions: Selonsertib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 5
States / cities: Denver, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Alzheimer's Disease
Interventions: CHF 5074, CHF 5974; Drug
Lead sponsor: CERESPIR; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: DTG, RPV, DTG/RPV FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Imlunestrant (Test), Imlunestrant (Reference), Omeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: South Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 2 more

Conditions: Kidney Transplantation
Interventions: Myfortic; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Malignancies, Solid Tumor, Hematological Malignancy
Interventions: Pelabresib; Drug
Lead sponsor: Constellation Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Akashi Therapeutics; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Nausea
Interventions: Questionnaires, 4 channel electrogastrogram (EGG), 36 channel high resolution electrogastrogram (HR-EGG), Magnetogastrogram (MGG), Electrocardiogram (EKG), Ondansetron, Cyproheptadine Oral Tablet; Diagnostic Test · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 8 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: LY4100511 (DC-853), Placebo; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity
Interventions: S-309309, Midazolam, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: MORF-057, Placebo for MORF-057; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Malaria: Relative Bioavailability and Food Effect of DSM265

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

A Study of Prasugrel in Healthy Participants

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

A Study of Imlunestrant (LY3484356) in Healthy Female Participants

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

Noninvasive Markers of Functional Nausea in Children

A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

A Study to Assess S-309309 in Healthy and Obese Participants

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers